AHI Welcomes FDA Action on Unapproved Drugs
(December 14, 2023) AHI welcomes the announcement of the Food and Drug Administration’s (FDA) action to issue warning letters to nine manufacturers and distributors who were marketing unapproved and misbranded antimicrobial animal drugs. This action is consistent with the work done by animal drug companies and FDA’s Center for Veterinary Medicine (CVM) to advance antimicrobial […]